ZA200602762B - Use of gaboxadol for treating insomnia - Google Patents
Use of gaboxadol for treating insomnia Download PDFInfo
- Publication number
- ZA200602762B ZA200602762B ZA200602762A ZA200602762A ZA200602762B ZA 200602762 B ZA200602762 B ZA 200602762B ZA 200602762 A ZA200602762 A ZA 200602762A ZA 200602762 A ZA200602762 A ZA 200602762A ZA 200602762 B ZA200602762 B ZA 200602762B
- Authority
- ZA
- South Africa
- Prior art keywords
- gaboxadol
- amount
- pharmaceutical composition
- insomnia
- medicament
- Prior art date
Links
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 title claims description 105
- 229950004346 gaboxadol Drugs 0.000 title claims description 104
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 title claims description 72
- 206010022437 insomnia Diseases 0.000 title claims description 58
- 238000011282 treatment Methods 0.000 claims description 49
- 239000003814 drug Substances 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 239000002253 acid Substances 0.000 claims description 14
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 239000007787 solid Substances 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 9
- -1 ion monohydrate Chemical class 0.000 claims description 8
- 238000011866 long-term treatment Methods 0.000 claims description 7
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 230000007958 sleep Effects 0.000 description 16
- 230000000694 effects Effects 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 230000001684 chronic effect Effects 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 208000019116 sleep disease Diseases 0.000 description 6
- 239000002585 base Substances 0.000 description 5
- 208000020016 psychiatric disease Diseases 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000037322 slow-wave sleep Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical compound OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000000224 Night Terrors Diseases 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 206010062519 Poor quality sleep Diseases 0.000 description 2
- 208000005439 Sleep paralysis Diseases 0.000 description 2
- 206010041010 Sleep terror Diseases 0.000 description 2
- 206010041235 Snoring Diseases 0.000 description 2
- 208000008548 Tension-Type Headache Diseases 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 2
- 201000001098 delayed sleep phase syndrome Diseases 0.000 description 2
- 208000033921 delayed sleep phase type circadian rhythm sleep disease Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 150000007522 mineralic acids Chemical group 0.000 description 2
- 201000003631 narcolepsy Diseases 0.000 description 2
- 206010029410 night sweats Diseases 0.000 description 2
- 230000036565 night sweats Effects 0.000 description 2
- 150000007524 organic acids Chemical group 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 201000002859 sleep apnea Diseases 0.000 description 2
- 208000020685 sleep-wake disease Diseases 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- QXQAPNSHUJORMC-UHFFFAOYSA-N 1-chloro-4-propylbenzene Chemical compound CCCC1=CC=C(Cl)C=C1 QXQAPNSHUJORMC-UHFFFAOYSA-N 0.000 description 1
- HCYFGRCYSCXKNQ-UHFFFAOYSA-N 2-(1,3-dimethyl-2,6-dioxo-7-purinyl)acetic acid Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)=O)C=N2 HCYFGRCYSCXKNQ-UHFFFAOYSA-N 0.000 description 1
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
- DPZHKLJPVMYFCU-UHFFFAOYSA-N 2-(5-bromopyridin-2-yl)acetonitrile Chemical compound BrC1=CC=C(CC#N)N=C1 DPZHKLJPVMYFCU-UHFFFAOYSA-N 0.000 description 1
- OZDAOHVKBFBBMZ-UHFFFAOYSA-N 2-aminopentanedioic acid;hydrate Chemical compound O.OC(=O)C(N)CCC(O)=O OZDAOHVKBFBBMZ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- SKTFQHRVFFOHTQ-UHFFFAOYSA-N 8-bromo-1,3-dimethyl-7h-purine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Br)=N2 SKTFQHRVFFOHTQ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Natural products O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229950003769 acefylline Drugs 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- HNEGQIOMVPPMNR-IHWYPQMZSA-N citraconic acid Chemical compound OC(=O)C(/C)=C\C(O)=O HNEGQIOMVPPMNR-IHWYPQMZSA-N 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000009837 dry grinding Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000002329 esterase inhibitor Substances 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000008667 sleep stage Effects 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 230000037046 slow wave activity Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000001238 wet grinding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200301877 | 2003-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200602762B true ZA200602762B (en) | 2007-06-27 |
Family
ID=34684447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200602762A ZA200602762B (en) | 2003-12-18 | 2004-12-14 | Use of gaboxadol for treating insomnia |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1720547A1 (ru) |
| JP (1) | JP2007515415A (ru) |
| KR (1) | KR20060103335A (ru) |
| CN (1) | CN1893942A (ru) |
| AR (1) | AR047154A1 (ru) |
| AU (1) | AU2004298313A1 (ru) |
| BR (1) | BRPI0415893A (ru) |
| CA (1) | CA2550610A1 (ru) |
| EA (1) | EA200600989A1 (ru) |
| IL (1) | IL176239A0 (ru) |
| IS (1) | IS8390A (ru) |
| MX (1) | MXPA06006685A (ru) |
| NO (1) | NO20063320L (ru) |
| SG (1) | SG133601A1 (ru) |
| TW (1) | TW200528098A (ru) |
| WO (1) | WO2005058313A1 (ru) |
| ZA (1) | ZA200602762B (ru) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0402118D0 (en) | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
| EP1906953A4 (en) * | 2005-04-29 | 2009-05-20 | Lundbeck & Co As H | FORMS OF ACID SALTS AND BASIC SALTS OF GABOXADOL |
| WO2019055369A1 (en) * | 2017-09-12 | 2019-03-21 | Ovid Therapeutics Inc. | USE OF GABOXADOL IN THE TREATMENT OF NARCOLEPSIA |
| EP3833351A4 (en) | 2018-09-20 | 2021-10-13 | Ovid Therapeutics Inc. | USE OF GABOXADOL TO TREAT TOURETTE SYNDROME, TICKS, AND STUTTERS |
| AU2019405489A1 (en) | 2018-12-17 | 2021-06-10 | Ovid Therapeutics Inc. | Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder |
| WO2021127308A1 (en) | 2019-12-18 | 2021-06-24 | Ovid Therapeutics Inc. | GABOXADOL FOR THERAPEUTIC TREATMENT OF 1p36 DELETION SYNDROME |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19525598C2 (de) * | 1995-07-13 | 1997-09-25 | Max Planck Gesellschaft | Schlafmittel |
| JP2004530695A (ja) * | 2001-05-21 | 2004-10-07 | ハー・ルンドベック・アクチエゼルスカベット | ガボキサドールの顆粒状調合物 |
-
2004
- 2004-12-07 TW TW093137759A patent/TW200528098A/zh unknown
- 2004-12-14 CA CA002550610A patent/CA2550610A1/en not_active Abandoned
- 2004-12-14 BR BRPI0415893-8A patent/BRPI0415893A/pt not_active IP Right Cessation
- 2004-12-14 WO PCT/DK2004/000861 patent/WO2005058313A1/en active Application Filing
- 2004-12-14 KR KR1020067011921A patent/KR20060103335A/ko not_active Application Discontinuation
- 2004-12-14 CN CNA2004800372437A patent/CN1893942A/zh active Pending
- 2004-12-14 ZA ZA200602762A patent/ZA200602762B/en unknown
- 2004-12-14 JP JP2006544213A patent/JP2007515415A/ja not_active Withdrawn
- 2004-12-14 EA EA200600989A patent/EA200600989A1/ru unknown
- 2004-12-14 AU AU2004298313A patent/AU2004298313A1/en not_active Abandoned
- 2004-12-14 SG SG200704528-9A patent/SG133601A1/en unknown
- 2004-12-14 EP EP04803014A patent/EP1720547A1/en not_active Withdrawn
- 2004-12-14 MX MXPA06006685A patent/MXPA06006685A/es unknown
- 2004-12-17 AR ARP040104752A patent/AR047154A1/es not_active Application Discontinuation
-
2006
- 2006-03-30 IS IS8390A patent/IS8390A/is unknown
- 2006-06-11 IL IL176239A patent/IL176239A0/en unknown
- 2006-07-18 NO NO20063320A patent/NO20063320L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR047154A1 (es) | 2006-01-11 |
| TW200528098A (en) | 2005-09-01 |
| BRPI0415893A (pt) | 2007-01-09 |
| MXPA06006685A (es) | 2006-08-23 |
| CA2550610A1 (en) | 2005-06-30 |
| SG133601A1 (en) | 2007-07-30 |
| CN1893942A (zh) | 2007-01-10 |
| WO2005058313A1 (en) | 2005-06-30 |
| AU2004298313A1 (en) | 2005-06-30 |
| KR20060103335A (ko) | 2006-09-28 |
| JP2007515415A (ja) | 2007-06-14 |
| EP1720547A1 (en) | 2006-11-15 |
| IL176239A0 (en) | 2006-10-05 |
| IS8390A (is) | 2006-03-30 |
| NO20063320L (no) | 2006-07-18 |
| EA200600989A1 (ru) | 2006-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2226582C (en) | Non-allosteric gabaa agonists for treating sleep disorders | |
| US9700548B2 (en) | Antihistamines combined with dietary supplements for improved health | |
| HU217136B (hu) | Riluzol alkalmazása Parkinson-kór és Parkinson-szindrómák kezelésére szolgáló gyógyszerkészítmények előállítására | |
| EA012176B1 (ru) | Новое применение пептидных соединений для лечения боли при болезненной диабетической нейропатии | |
| CA2561883A1 (en) | Treatment of impaired respiratory function with gaboxadol | |
| WO2000025821A1 (en) | Method of treating and diagnosing restless legs syndrome and corresponding means | |
| US20050137222A1 (en) | Treatment of insomnia in human patients | |
| US20070299048A1 (en) | Combination of Gaboxadol and 5Ht2 Antagonists | |
| ZA200602762B (en) | Use of gaboxadol for treating insomnia | |
| JP2007515415A6 (ja) | 不眠症の治療にガボクサドールを使用する方法 | |
| MXPA06015196A (es) | Tratamiento del dolor neuropatico, la fibromialgia o la artritis reumatoide. | |
| JPH0196131A (ja) | 睡眠障害および鬱病を治療するためのある種の化合物の使用 | |
| RU2445100C2 (ru) | Консервативный способ комплексного лечения острых и хронических анальных трещин | |
| Richards et al. | (312/759): ALGRX 4975 reduces pain of acute lateral epicondylitis: Preliminary results from a randomized, double-blind, placebo-controlled, phase II multicenter clinical trial | |
| EP1611901B1 (en) | Preventive or remedy for teeth grinding | |
| WO1995011679A1 (en) | Use of lobeline for the treatment of nicotine withdrawal | |
| JP2019006717A (ja) | 経口睡眠改善剤 | |
| Weber et al. | (312/776): Efficacy and safety of tapentadol HCl in patients with pain after bunionectomy | |
| AU736514B2 (en) | Non-allosteric gabaa agonists for treating sleep disorders | |
| US20190008188A1 (en) | Antihistamines Combined with Dietary Supplements for Improved Health | |
| JP2022529290A (ja) | 呼吸性不整脈を処置するための方法および組成物 | |
| Alkhamesi et al. | (312/756): Aerosolized bupivacaine reduces post-laparoscopic pain: A randomized controlled double blinded clinical trial | |
| Secaucus | D11-Non-Opioid Analgesics: Other | |
| Backonja et al. | (312/745): Gabapentin exposure and pain reduction in patients with postherpetic neuralgia: analysis of a phase 2a randomized, double-blind, placebo controlled study of neurontin and XP13512 |